PD-L1 Antibody – 149Sm

Catalog: 714901                                          Clone: E1L3N                                            Isotype: Rabbit IgG
Reactivity: Human*
Storage: PD-L1 antibody is supplied in antibody stabilizer with 0.05% sodium azide. Store at 4°C
IHC: PD-L1 antibody staining of FFPE human placenta
MIBI: PD-L1 antibody staining (cyan) of FFPE human placenta, counterstained with dsDNA (magenta)
IHC: PD-L1 antibody staining of FFPE human tonsil
MIBI: PD-L1 antibody staining (cyan) of FFPE human tonsil, counterstained with dsDNA (magenta)
Background: Programmed cell death 1 ligand 1 (PD-L1, CD274) binds to PD-1 and inhibits T cell activation. APCs, activated T cells, and tissues including placenta, heart, and lung can express PD-L1. PD-L1 is expressed in cancer as a means for cancerous cells to inhibit immune responses. PD-L1 has been detected for several tumor types including melanoma, lung, ovary, colon, breast, and renal cell carcinomas. PD-L1 expression in cancer is associated with tumor infiltrating lymphocytes, which mediate PD-L1 expression through the release of interferon gamma. Inhibition of the PD-1-PD-L1 axis has been an active area of clinical research with several approved drugs for multiple indications.

Validation: Each lot of conjugated PD-L1antibody is quality control tested by MIBIscope™ analysis of stained tissue microarray using the appropriate positive and negative tissue field of views and are pathologist verified.

Recommended Usage: 1 uL of PD-L1 antibody per 100 uL staining volume using the MIBI™ Staining Protocol.
For optimal results, antibody should be titrated for each desired application.  Suggested starting range is 1:100.

MIBI technology: Learn more about MIBI Technology, a multiplex IHC technology with unmatched sensitivity and true subcellular resolution.


  • Wimberly, H. et al. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res. 2015; 3(4): 326-332.
  • Bindels, S. et al. Regulation of PD-L1 by SIP1 in human epithelial breast tumor cells. Oncogene. 2006; 25:4975–4985.

* Conjugate tested on human tissue.

Contact Us

Let us know how we can help you.

    Immuno-oncology/CancerNeuroscienceInfectious DiseaseImmunologyStem CellOther


    Contact Us